why choose us

First received: August 26, 2022

Clinical Trial: Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pediatric Brain Tumor

Study Type: INTERVENTIONAL


Official Title: Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Brief Summary: This is a longitudinal, dose-finding, open label safety and tolerability phase Ib treatment study.The study hypothesis is that dapagliflozin will be well-tolerated by brain tumor patients on chemotherapy as assessed by tolerability and side effect profiles.

Read more